Trial Profile
Aprepitant to Mitigate Opioids' Cognitive Side Effects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 May 2017
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
- Focus Therapeutic Use
- Acronyms CognAp
- 01 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 30 Aug 2014 New trial record